Regeneron announces positive phase 3 trial in adults with ultra-rare genetic disorder fibrodysplasia ossificans progressiva (fop), demonstrating that garetosmab prevents greater than 99% of abnormal bone formation

Fop is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation
REGN Ratings Summary
REGN Quant Ranking